|
1
|
Correia NC and Barata JT: MicroRNAs and
their involvement in T-ALL: A brief overview. Adv Biol Regul.
74(100650)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Litzow MR and Ferrando AA: How i treat
T-cell acute lymphoblastic leukemia in adults? Blood. 126:833–841.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hounjet J, Habets R, Schaaf MB, Hendrickx
TC, Barbeau LM, Yahyanejad S, Rouschop KM, Groot AJ and Vooijs M:
The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1
driven human T-ALL to γ-secretase inhibition. Oncogene.
38:5457–5468. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lange A, Dlubek D, Zdziarski R,
Chodorowska A, Mordak-Domagala M, Klimczak A, Lange J and Jaskula
E: Donor lymphocyte infusions to leukemic bone lesions are
therapeutically effective in a ph+ all patient with
post-HSCT relapse. J Immunotoxico. 11:347–352. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Follini E, Marchesini M and Roti G:
Strategies to overcome resistance mechanisms in T-cell acute
lymphoblastic leukemia. Int J Mol Sci. 20(3021)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ali N, Flutter B, Rodriguez RS, Paghaleh
ES, Barber LD, Lombardi G and Nestle FO: Xenogeneic
graft-versus-host-disease in NOD-scid IL-2rγnull mice display a
T-effector memory phenotype. PLoS One. 7(e44219)2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gill S, Tasian SK, Ruella M, Shestova O,
Li Y, Porter DL, Carroll M, Desnoyers GD, Scholler J, Grupp SA, et
al: Preclinical targeting of human acute myeloid leukemia and
myeloablation using chimeric antigen receptor-modified T cells.
Blood. 123:2343–2354. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Riegel C, Boeld TJ, Doser K, Huber E,
Hoffmann P and Edinger M: Efficient treatment of murine acute GvHD
by in vitro expanded donor regulatory T cells. Leukemia.
34:895–908. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kuhlen M, Willasch AM, Dalle JH, Wachowiak
J, Yaniv I, Ifversen M, Sedlacek P, Guengoer T, Lang P, Bader P, et
al: Outcome of relapse after allogeneic HSCT in children with ALL
enrolled in the ALL-SCT 2003/2007 trial. Br J Haematol. 180:82–89.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pui CH, Pei DQ, Cheng C, Tomchuck SL,
Evans SN, Inaba H, Jeha S, Raimondi SC, Choi JK, Thomas Paul G and
Dallas MH: Treatment response and outcome of children with T-cell
acute lymphoblastic leukemia expressing the gamma-delta T-cell
receptor. Oncoimmunology. 8(1599637)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hefazi M and Litzow MR: Recent advances in
the biology and treatment of T cell acute lymphoblastic leukemia.
Curr Hematol Malig Rep. 13:265–274. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Drury RE, O'Connor D and Pollard AJ: The
clinical application of microRNAs in infectious disease. Front
Immunol. 8(1182)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lin T, Zhou SM, Gao H, Li YQ and Sun LJ:
MicroRNA-325 is a potential biomarker and tumor regulator in human
bladder cancer. Technol Cancer Res Treat.
17(1533033818790536)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yooa B, Ghosha SK, Kumar M, Moore A, Yigit
MV and Medarova Z: Design of nanodrugs for miRNA targeting in tumor
cells. J Biomed Nanotechnol. 10:1114–1122. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ingenito F, Roscigno G, Affinito A, Nuzzo
S, Scognamiglio I, Quintavalle C and Condorelli G: The Role of
Exo-miRNAs in cancer: A focus on therapeutic and diagnostic
applications. Int J Mol Sci. 20(4687)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li H, Huang W and Luo R: The microRNA-325
inhibits hepatocellular carcinoma progression by targeting high
mobility group box 1. Diagn Pathol. 10(117)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang Z, Han Y, Sun G, Liu X, Jia X and Yu
X: MicroRNA-325-3p inhibits cell proliferation and induces
apoptosis in hepatitis B virus-related hepatocellular carcinoma by
down-regulation of aquaporin 5. Cell Mol Biol Lett.
24(13)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yao SH, Zhao TJ and Jin H: Expression of
microRNA-325-3p and its potential functions by targeting HMGB1 in
non-small cell lung cancer. Biomed Pharmacother. 70:72–79.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qin L, Guo J, Zheng Q and Zhang H: BAG2
structure, function and involvement in disease. Cell Mol Biol Lett.
21(18)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ge F, Zhang L, Tao SC, Kitazato K, Zhang
ZP, Zhang XE and Bi LJ: Quantitative proteomic analysis of tumor
reversion in multiple myeloma cells. J Proteome Res. 10:845–855.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yang KM, Bae E, Ahn SG, Pang K, Park Y,
Park J, Lee J, Ooshima A, Park B, Kim J, et al: Co-chaperone BAG2
determines the pro-oncogenic role of cathepsin B in triple-negative
breast cancer cells. Cell Rep. 21:2952–2964. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang XY, Hong SS, Zhang M, Cai QQ, Zhang
MX and Xu CJ: Proteomic alterations of fibroblasts induced by
ovarian cancer cells reveal potential cancer targets. Neoplasma.
65:104–112. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yue X, Zhao Y, Liu J, Zhang C, Yu H, Wang
J, Zheng T, Liu L, Li J, Feng Z and Hu W: BAG2 promotes
tumorigenesis through enhancing mutant p53 protein levels and
function. Elife. 4(e08401)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xia W, Cao G and Shao N: Progress in miRNA
target prediction and identification. Sci China C Life Sc.
52:1123–1130. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sun L, Chen G, Sun AQ, Wang Z, Huang H,
Gao Z, Liang W, Liu C and Li K: BAG2 promotes proliferation and
metastasis of gastric cancer via ERK1/2 signaling and partially
regulated by miR186. Front Onco. 10(31)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Selmansberger M, Feuchtinger A, Zurnadzhy
L, Michna A, Kaiser JC, Abend M, Brenner A, Bogdanova T, Walch A,
Unger K, et al: CLIP2 as radiation biomarker in papillary thyroid
carcinoma. Oncogene. 34:3917–3925. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ge Y, Yan D, Deng H, Chen W and An G:
Novel molecular regulators of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis in NSCLC cells.
Clin Lab. 61:1855–1863. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jamali L, Tofigh R, Tutunchi S, Panahi G,
Borhani F, Akhavan S, Nourmohammadi P, Ghaderian SMH, Rasouli M and
Mirzaei H: Circulating microRNAs as diagnostic and therapeutic
biomarkers in gastric and esophageal cancers. J Cell Physiol.
233:8538–8550. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kwan JY, Psarianos P, Bruce JP, Yip KW and
Liu FF: The complexity of microRNAs in human cancer. J Radiat Res.
57 (Suppl):106–111. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
D'Angelo B, Benedetti E, Cimini A and
Giordano A: MicroRNAs: A puzzling tool in cancer diagnostics and
therapy. Anticancer Res. 36:5571–5575. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pehlivan KC, Duncan BB and Lee DW: CAR-T
cell therapy for acute lymphoblastic leukemia: Transforming the
treatment of relapsed and refractory disease. Curr Hematol Malig
Rep. 13:396–406. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Vairy S, Garcia JL, Teira P and
Bittencourt H: CTL019 (tisagenlecleucel): CAR-T therapy for
relapsed and refractory B-cell acute lymphoblastic leukemia. Drug
Des Devel Ther. 12:3885–3898. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang
H, Hong M, Jiang T, Jiang Q, Lu J, et al: An oncogenic role of
miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by
targeting glucocorticoid receptor-a and cAMP/PKA pathways.
Leukemia. 26:769–777. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang H, Ji W, Huang R, Li L, Wang X, Li
L, Fu X, Sun Z, Li Z, Chen Q and Zhang M: MicroRNA-155 is a
potential molecular marker of natural killer/T-cell lymphoma.
Oncotarget. 7:53808–53819. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Saki N, Abroun S, Soleimani M, Mortazavi
Y, Kaviani S and Arefian E: The roles of miR-146a in the
differentiation of Jurkat T-lymphoblasts. Hematology. 19:141–147.
2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Abe F, Kitadate A, Ikeda S, Yamashita J,
Nakanishi H, Takahashi N, Asaka C, Teshima K, Miyagaki T, Sugaya M
and Tagawa H: Histone deacetylase inhibitors inhibit metastasis by
restoring a tumor suppressive microRNA-150 in advanced cutaneous
T-cell lymphoma. Oncotarget. 8:7572–7585. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Takahashi RU, Prieto-Vila M, Hironaka A
and Ochiya T: The role of extracellular vesicle microRNAs in cancer
biology. Clin Chem Lab Med. 55:648–656. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Senkevitch E, Li W, Hixon JA, Andrews C,
Cramer SD, Pauly GT, Back T, Czarra K and Durum SK: Inhibiting
Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic
leukemia with IL7-Rα mutations. Oncotarget. 9:22605–22617.
2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zadi Heydarabad M, Vatanmakanian M,
Abdolalizadeh J, Mohammadi H, Azimi A, Mousavi Ardehaie R,
Movasaghpour A and Farshdousti Hagh M: Apoptotic effect of
resveratrol on human T-ALL cell line CCRF-CEM is unlikely exerted
through alteration of BAX and BCL2 promoter methylation. J Cell
Biochem. 119:10033–10040. 2018.PubMed/NCBI View Article : Google Scholar
|
